Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice

Glauben, A.; Batra, A.; Stroh, T.; Erben, U.; Fedke, I.; Lehr, H. A.; Leoni, F.; Mascagni, P.; Dinarello, C. A.; Zeitz, M.; Siegmund, B.
May 2008
Gut;May2008, Vol. 57 Issue 5, p613
Academic Journal
OBJECTIVE: Inhibition of histone deacetylases, well known for its antiproliferative efficacy in vivo, was recently shown to ameliorate inflammation in experimental colitis. Since inflammatory bowel disease is associated with an increased risk of developing colon cancer, here the combined anti-inflammatory and proapoptotic efficacy of histone deacetylase inhibitors was studied in mouse models. METHODS: The novel histone deacetylase inhibitor ITF2357 was compared with suberoylanilide hydroxamic acid in models of experimental colitis. Effects on tumour growth were studied after treatment of mice with azoxymethane and dextran sulphate sodium, and in interleukin 10 (IL10) knockout mice, respectively. Possible underlying mechanisms involving apoptosis and nuclear factor (NF)-κB activation were addressed by flow cytometry and western blot. RESULTS: In dextran sulphate sodium- and trinitrobenzene sulphonic acid-induced colitis, treatment with ITF2357 was superior to suberoylanilide hydroxamic acid as shown by macroscopic and histological amelioration of inflammation, by reduced production of interferon γ (IFN γ) and by increased production of IL10. In both models of inflammation-mediated tumourigenesis, inhibition of histone deacetylases resulted in a significant suppression of tumour growth in terms of size and number, along with reduced signs of inflammation. As for potential mechanisms of ITF2357 action, increased acetylation of histone 3, reduced production of IFN γ and enhanced apoptosis in lamina propria mononuclear cells were found to accompany a histone deacetylase-dependent activation of NF-κB. CONCLUSIONS: These results indicate that inhibition of histone deactylases can attenuate inflammation-mediated tumour growth, which is paralled by an inhibition of NF-κB. Thus histone deacetylase inhibitors provide a promising strategy that combines anti-inflammatory and proapoptotic modes of action.


Related Articles

  • Butyric acid attenuates intestinal inflammation in murine DSS-induced colitis model via milk fat globule-EGF factor 8. Mishiro, Tsuyoshi; Kusunoki, Ryusaku; Otani, Aya; Ansary, Md Mesbah Uddin; Tongu, Miki; Harashima, Nanae; Yamada, Takaya; Sato, Shuichi; Amano, Yuji; Itoh, Kazuhito; Ishihara, Shunji; Kinoshita, Yoshikazu // Laboratory Investigation (00236837);Jul2013, Vol. 93 Issue 7, p834 

    Butyric acid, a short-chain fatty acid and one of the main metabolites of intestinal microbial fermentation of dietary fiber, has been shown to have an important role in maintaining the integrity of the intestinal mucosa, while it also has been shown to exert potent anti-inflammatory effects...

  • Inhibition of Histone Deacetylases in Inflammatory Bowel Diseases. Glauben, Rainer; Siegmund, Britta // Molecular Medicine;May/Jun2011, Vol. 17 Issue 5/6, p426 

    This review, comprised of our own data and that of others, provides a summary overview of histone deacetylase (HDAC) inhibition on intestinal inflammation as well as inflammation-mediated carcinogenesis. Experimental colitis in mice represents an excellent in vivo model to define the specific...

  • Metastasis: When good drugs do bad things. Seton-Rogers, Sarah // Nature Reviews Cancer;Apr2009, Vol. 9 Issue 4, p228 

    The article discusses two studies which have shown that inhibition of angiogenesis can result in increased tumour invasion and metastasis. One study found that short-term DC101 treatment significantly increased the number of mice with long-term lymph node and liver metastases. Another study...

  • Therapie chronisch-entzündlicher Darmerkrankungen. Mecklenburg, Ingo // Praxis (16618157);2/12/2014, Vol. 103 Issue 4, p203 

    Inflammatory Bowel Disease (i.e. Crohn's Disease and Ulcerative Colitis) show a rising incidence throughout Switzerland. An early and individualized therapy usually enables the effective treatment of both diseases and prevents structural gastrointestinal damage or surgical interventions. The...

  • Signalling: All together now. McCarthy, Nicola // Nature Reviews Cancer;Dec2012, Vol. 12 Issue 12, p794 

    The article presents a study that investigates the interaction of hailstone deacetylase 6 (HDAC6) and CD133 and its impact on tumor xenograft growth in the U.S.

  • Natalizumab.  // Reactions Weekly;6/25/2005, Issue 1057, p14 

    Discusses research being done on progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. Reference to a study by G. Van Assche et al published in the 2005 issue of the "New England Journal of Medicine"; Findings of the study.

  • RIG-I has guts: Identification of a role for RIG-I in colitis development. Solis, Mayra; Goubau, Delphine; Hiscott, John // Cell Research;Dec2007, Vol. 17 Issue 12, p974 

    The article discusses a research study that reveals the differences of two forms of inflammatory bowel disease (IBD) which pointed that environmental and genetic factors plays significant roles to pathogenesis and susceptibility to IBD. Related research conducted to mice displayed similarity to...

  • Manchester University heads £10m EU-funded research network into inflammatory bowel disease.  // Gastrointestinal Nursing;Apr2013, Vol. 11 Issue 3, p6 

    The article reports that the University of Manchester is leading a 10 million Sterling Pound, 5-year research network to identify better treatments for inflammatory bowel diseases (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC).

  • Pyoderma Gangrenosum Associated With Inflammatory Bowel Disease. Report of Two Cases With Good Response to Infliximab. Carrasco Cubero, Carmen; Ruiz Tudela, M. Mar; Salaberri Maestrojuan, José Javier; Pérez Venegas, José Javier // Reumatologia Clinica;mar/abr2012, Vol. 8 Issue 2, p90 

    Among the extraintestinal manifestations of inflammatory bowel disease (IBD), pyoderma gangrenosum (PG) often poses a therapeutic challenge. We describe two cases of PG associated with inflammatory bowel disease, who responded to treatment with Infliximab.


Read the Article


Sign out of this library

Other Topics